Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

fer and provide contact with its network of physicians and patient organizations. The purchase price is undisclosed but divided into an up-front payment and commercial milestone payments.

The PPS product opportunity is an important means to provide a treatment to a patient group largely suffering without effective medication and to expand sales of immunoglobulin in new patient segments.

About PPS

Several decades after suffering acute polio infection survivors commonly develop PPS characterized by new or increased muscle weakness, fatigue, and pain. Ongoing denervation is the most often suggested for increased muscle weakness associated with polio infection.

Patients with PPS have increased expression of mRNA for proinflammatory cytokines in cerebrospinal fluid which suggests an inflammatory process in the central nervous system. Some patients with asymmetrical weakness have increased wear and tear on joints and muscles, including breathing muscles.

While rarely fatal, the neurological and muscular symptoms of PPS are lifelong and debilitating.

The most recent polio epidemic culminated in the Western countries around 1950. As most infections occur in children, there is nowadays a large pool of polio survivors with varying degrees of functional decline. US National Institute of Neurological Disorders and Stroke (NINDS) gives a prevalence interval for PPS of 25 to 50% (in primary polio infection survivors), WHO estimates a 40 % prevalence; assuming a prevalence of 30%, only in major Western countries there would be around 300,000 PPS patients.

Currently there is no pharmacological treatment for PPS. Several therapeutic agents have failed in achieving positive outcomes. Treatment practices are based on physiotherapy
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Madison, WI (PRWEB) May 24, 2013 ... to the discovery and development of calcium-binding proteins ... publication of safety assessment study of apoaequorin ... an international journal published for the British Industrial ... the study was to investigate potential adverse effects, ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...
(Date:5/23/2013)... , May 23, 2013 BioTrends Research ... advisory firms for specialized biopharmaceutical issues, finds that, ... infectious disease specialists reported that in the past ... intentionally delaying treatment) in anticipation of the next ... months ago, when only 6 percent reported that ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... Innovex,s best-in-class sales coaching tool, powered by ... Award for Sales, CHICAGO and BRACKNELL, ... received the Ventana Research 2007 Operational Performance,Leadership ... excellence in,orchestrating people, process, information and technology ...
... MEETING, Pa., Nov. 9 Genaera,Corporation (Nasdaq: GENR ... nine-month periods ended September 30, 2007. The net loss ... million, or,$(0.21) per basic and diluted share, as compared ... basic and diluted share, for the three-month period,ended September ...
... skin tests at once with minimal patient discomfort, ... Unit announced today the launch of the ComforTen(TM) ... The device features ten,surgical steel 1.2mm lancet tips, ... ComforTen is the only 10-test, self-loading,surgical steel testing ...
Cached Biology Technology:ForceLogix, Innovex Win Sales Operational Performance Award 2ForceLogix, Innovex Win Sales Operational Performance Award 3Genaera Corporation Announces Third Quarter Financial Results 2Genaera Corporation Announces Third Quarter Financial Results 3Genaera Corporation Announces Third Quarter Financial Results 4Genaera Corporation Announces Third Quarter Financial Results 5HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3
(Date:5/22/2013)... a novel technique that can detect molecular variants in ... one of the most important, though time-consuming, processes in ... in Nature , post-doctoral researcher David Patterson, Professor ... the Center for Free-Electron Laser Science (CFEL) in Hamburg, ... fields to identify molecular variants apart, and to determine ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
(Date:5/22/2013)... bacteria is responsible for legionellosis, an infectious disease ... us, this pathogen has developed a complex method enabling ... cells, thus avoiding these acting against the infectious bacteria. ... CIC bioGUNE, in which teams from the National Institute ... Supercomputation Centre in Barcelona (BSC) have also participated, has ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Mechanism discovered which aids Legionella to camouflage itself in the organism 2
... (a local area of bulge) in the abdominal aortathe largest ... fact, about half of these patients don,t make it to ... not face open surgery to repair the blood vessel. This ... ruptured aneurysms called endovascular aneurysm repair (EVAR) is safer than ...
... for sustainability of the ocean,s fisheries, solutions can be found ... a study published on March 23 in the journal ... fisheries yields over seven centuries of human habitation in Hawaii ... the United States, and evaluated the management strategies associated with ...
... skilled at patching up damage that would stop normal cells ... protective caps at the end of each chromosome. Loss ... into a growth arrest state called "senescence," but cancer cells ... eroded telomeres. If telomerase fails to activate, the tumor ...
Cached Biology News:Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality 2Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality 3Ancient civilizations reveal ways to manage fisheries for sustainability 2Ancient civilizations reveal ways to manage fisheries for sustainability 3Salk scientists open new window into how cancers override cellular growth controls 2Salk scientists open new window into how cancers override cellular growth controls 3